Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects-Reference-Cited by-同舟云学术

Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects

Published:2022-07-19 Issue:7 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Rodvold Keith A.¹^ORCID,Gotfried Mark H.¹²,Gupta Vipul³^ORCID,Ek Amanda³,Srivastava Praveen³,Talley Angela³,Bruss Jon³

Affiliation:

1. University of Illinois—Chicago, Chicago, Illinois, USA

2. Pulmonary Associates, PA, Phoenix, Arizona, USA

3. Spero Therapeutics, Inc., Cambridge, Massachusetts, USA

Abstract

Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral carbapenem prodrug being developed for the treatment of serious bacterial infections. The active moiety, tebipenem, has broad-spectrum activity against commonEnterobacteralespathogens, including extended-spectrum-β-lactamase (ESBL)-producing multidrug-resistant strains.

Funder

DHHS Office of the Secretary, BARDA

Spero Therapeutics

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00590-22

Reference30 articles.

1. Tebipenem, the first oral carbapenem antibiotic

2. Characterization of SPR994, an Orally Available Carbapenem, with Activity Comparable to Intravenously Administered Carbapenems